Physician profile
Dianne Marie David
NPI 1285149229
$9,573.22
in general payments reported to CMS, 2019-2025
35 companies · $2,699 in 2025
The $2,699 reported for 2025 was more than what 99% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $890 · 2023: $2,402 · 2024: $3,583 · 2025: $2,699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,584 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,583.71 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,118.72 | 2022-2025 | |
| Ucb, INC. | $708.87 | 2023-2025 | Briviact, Rystiggo, Nayzilam |
| Argenx US, INC. | $653.74 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Mdd US Operations, LLC | $561.91 | 2023-2025 | Gocovri, Gocovri |
| Pfizer INC. | $547.05 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $512.63 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $481.56 | 2024-2025 | |
| Eisai INC. | $412.90 | 2024-2025 | |
| Sk Life Science, INC. | $408.94 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $338.93 | 2024-2025 | Acthar |
| Lilly USA, LLC | $334.13 | 2022-2025 | Amyvid, Emgality, Kisunla |
| Otsuka America Pharmaceutical, INC. | $319.72 | 2023-2025 | Rexulti |
| Genzyme Corporation | $317.18 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $316.09 | 2023-2025 | Hyqvia, Gammagard |
| Acadia Pharmaceuticals INC | $311.15 | 2022-2025 | Nuplazid, Daybue |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $304.48 | 2023-2025 | Ingrezza |
| Emd Serono, INC. | $221.47 | 2022-2025 | Mavenclad |
| Vanda Pharmaceuticals INC. | $193.28 | 2024-2025 | Ponvory |
| Amgen INC. | $187.20 | 2024-2025 | Uplizna |
| Amneal Pharmaceuticals LLC | $159.40 | 2022-2025 | Crexont, Rytary |
| Alexion Pharmaceuticals, INC. | $152.11 | 2023-2024 | Ultomiris, Soliris |
| Lundbeck LLC | $146.88 | 2023-2025 | Vyepti, Rexulti |
| Ani Pharmaceuticals, INC. | $122.55 | 2022-2025 | Purified Cortrophin Gel |
| Corium, LLC | $108.67 | 2023 | Adlarity |
| Biohaven Pharmaceutical Holding Company Ltd. | $107.53 | 2022 | |
| Genentech USA, INC. | $104.92 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Octapharma USA, INC. | $100.26 | 2022-2025 | Panzyga |
| Biogen, INC. | $81.04 | 2024-2025 | Leqembi, Skyclarys |
| Livanova USA, INC. | $72.18 | 2022 | |
| Grifols USA, LLC | $43.55 | 2025 | Gamunex-C |
| Catalyst Pharmaceuticals, INC. | $30.08 | 2024 | |
| Avion Pharmaceuticals | $28.90 | 2022 | |
| Horizon Therapeutics Plc | $25.70 | 2023 | Uplizna |
| Csl Behring | $22.16 | 2023 | Hizentra |
| Neurelis, INC. | $17.34 | 2024 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dianne David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.